OC
TVTX icon

Oppenheimer & Co’s Travere Therapeutics TVTX Stock Holding History

Oppenheimer & Co’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-48,139
Closed -$673K – 1648
2024
Q3 		$673K Buy
+48,139
New +$502K 0.01% 925

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Oppenheimer & Co's TVTX Position: Q4 2024 in Review

Oppenheimer & Co sold out of Travere Therapeutics (TVTX) in Q4 2024, closing a stake of 48,139 shares — an estimated $673K sold.

Oppenheimer & Co first reported a position in TVTX in Q3 2024 and held it in 1 quarter. The position peaked at $673K in Q3 2024. 197 funds tracked by Wall St. Rank hold TVTX as of Q4 2024.

  • Oppenheimer & Co reported no remaining Travere Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Oppenheimer & Co sold 48,139 Travere Therapeutics shares in Q4 2024, an estimated $673K.
  • Oppenheimer & Co first reported a position in Travere Therapeutics in Q3 2024 and held it in 1 quarter.
  • Oppenheimer & Co's Travere Therapeutics position peaked at $673K in Q3 2024.
  • 197 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2024.

Based on Oppenheimer & Co's 13F filing for Q4 2024, filed 5 Feb 2025.